DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 200 filers reported holding DENALI THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.71 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $212,572 | -32.3% | 10,304 | -3.1% | 0.01% | -30.0% |
| Q2 2023 | $313,957 | +20.2% | 10,639 | -6.2% | 0.02% | +25.0% |
| Q1 2023 | $261,251 | +27.9% | 11,339 | +54.4% | 0.02% | +45.5% |
| Q4 2022 | $204,209 | -52.4% | 7,343 | -23.6% | 0.01% | 0.0% |
| Q4 2021 | $429,000 | +41.6% | 9,610 | +59.8% | 0.01% | +37.5% |
| Q3 2021 | $303,000 | -22.5% | 6,012 | +20.7% | 0.01% | -33.3% |
| Q2 2021 | $391,000 | +58.3% | 4,983 | +68.9% | 0.01% | +100.0% |
| Q4 2020 | $247,000 | -24.2% | 2,950 | -67.6% | 0.01% | -62.5% |
| Q3 2020 | $326,000 | +23.5% | 9,100 | -16.6% | 0.02% | +6.7% |
| Q2 2020 | $264,000 | +169.4% | 10,909 | +158.0% | 0.02% | +150.0% |
| Q1 2019 | $98,000 | +139.0% | 4,229 | +113.9% | 0.01% | +100.0% |
| Q4 2018 | $41,000 | – | 1,977 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
| Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
| Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
| Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
| SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
| Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
| GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |